Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients

References

• van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427. doi:10.1016/S0140-6736(21)00135-5
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–477. doi:10.1001/jama.2022.0003
   PubMed Web of Science ®Google Scholar
• Silberstein J, Tuchman S, Grant SJ. What is multiple myeloma? JAMA. 2022;327(5):497. doi:10.1001/jama.2021.25306
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Swan D, Hayden PJ, Eikema DJ, et al. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. Br J Haematol. 2022;197(1):82–96. doi:10.1111/bjh.18025
   PubMed Web of Science ®Google Scholar
• Rafae A, Ehsan H, Wahab A, et al. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients. Crit Rev Oncol Hematol. 2022;176:103744. doi:10.1016/j.critrevonc.2022.103744
   PubMed Web of Science ®Google Scholar
• Facon T, San-Miguel J, Dimopoulos MA, et al. Treatment regimens for transplant-ineligible patients With newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(5):1976–1992. doi:10.1007/s12325-022-02083-8
   PubMed Web of Science ®Google Scholar
• Sandecka V, Pour L, Spicka I, et al. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. Eur J Haematol. 2021;107(4):466–474. doi:10.1111/ejh.13683
   PubMed Web of Science ®Google Scholar
• Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28(2):258–268. doi:10.1038/leu.2013.220
   PubMed Web of Science ®Google Scholar
• Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928–1937. doi:10.1200/JCO.19.02515
   PubMed Web of Science ®Google Scholar
• Ikebe E, Kawaguchi A, Tezuka K, et al. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice. Blood Cancer J. 2013;3(8):e132. doi:10.1038/bcj.2013.30
   PubMedGoogle Scholar
• Kuravi S, Parrott E, Mudduluru G, et al. CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. Blood Cancer J. 2019;9(2):14. doi:10.1038/s41408-019-0171-2
   PubMedGoogle Scholar
• Casas S, Ollila J, Aventin A, et al. Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genet Cytogenet. 2003;146(2):89–101. doi:10.1016/S0165-4608(03)00102-X
   PubMedGoogle Scholar
• Zang M, Guo J, Liu L, et al. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis. 2020;9(3):31. doi:10.1038/s41389-020-0216-1
   PubMed Web of Science ®Google Scholar
• Liu LT, Deng SH, Zang MR, et al. Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy. Zhonghua Xue Ye Xue Za Zhi. 2020;41(7):583–588.
   PubMedGoogle Scholar
• Prince TL, Lang BJ, Okusha Y, et al. Cdc37 as a Co-chaperone to Hsp90. Subcell Biochem. 2023;101:141–158. doi:10.1007/978-3-031-14740-1_5
   PubMedGoogle Scholar
• Zang MR, Liu LT, Deng SH, et al. Cdc37 expression in multiple myeloma and its role in cell proliferation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(5):1522–1527.
   PubMedGoogle Scholar
• Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992. doi:10.1038/leu.2013.293
   PubMed Web of Science ®Google Scholar
• Laurent V, Fronteau C, Antier C, et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2021;56(2):395–399. doi:10.1038/s41409-020-01033-8
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695. doi:10.1182/blood-2010-10-299487
   PubMed Web of Science ®Google Scholar
• Owen RG. Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging). Hemasphere. 2019;3(Suppl).
   PubMedGoogle Scholar
• Santon A, Garcia-Cosio M, Cristobal E, et al. Expression of heat shock proteins in classical Hodgkin lymphoma: correlation with apoptotic pathways and prognostic significance. Histopathology. 2011;58(7):1072–1080. doi:10.1111/j.1365-2559.2011.03803.x
   PubMed Web of Science ®Google Scholar
• Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36(5):494–504. doi:10.1016/j.humpath.2005.03.004
   PubMed Web of Science ®Google Scholar
• Ying WZ, Li X, Rangarajan S, et al. Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury. J Clin Invest. 2019;129(7):2792–2806. doi:10.1172/JCI125517
   PubMed Web of Science ®Google Scholar
• Mellors PW, Binder M, Ketterling RP, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020;4(10):2236–2244. doi:10.1182/bloodadvances.2019001275
   PubMed Web of Science ®Google Scholar
• Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21. doi:10.1038/s41408-022-00611-x
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang R, Xie S, et al. A novel identified necroptosis-related risk signature for prognosis prediction and immune infiltration indication in acute myeloid leukemia patients. Genes (Basel). 2022;13(10).
   Web of Science ®Google Scholar
• Zhao M, Ma J, Zhu HY, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the Trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011;10:104. doi:10.1186/1476-4598-10-104
   PubMed Web of Science ®Google Scholar
• D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–3418. doi:10.1200/JCO.21.02614
   PubMed Web of Science ®Google Scholar
• Cho HJ, Jung SH, Jo JC, et al. Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. Blood Cancer J. 2021;11(12):190. doi:10.1038/s41408-021-00577-2
   PubMed Web of Science ®Google Scholar